TENVIRA Tablet

Therapeutic Class

Antivirals

Indications

Tenvira is indicated for the treatment of chronic hepatitis B virus infection in adults over 18 years of age. It is also indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Chemical Composition

Each film-coated tablet contains Tenofovir Disoproxil Fumarate INN 300 mg equivalent to Tenofovir Disoproxil 245 mg.

Packaging

Each Box contains 10's tablet in alu-alu blister pack.

Dosage & Administration

Recommended dose in adults 18 years of age or older for the treatment of chronic hepatitis B infection: The recommended dose is 300 mg once daily with or without food. However, it is generally recommended to be taken with a meal to improve bioavailability. Usual adult dose for HIV infection: 300 mg orally once a day. Patients with renal impairment: No dosage adjustment is necessary for patients with mild renal impairment (creatinine clearance 50-80 mL/min). Since tenofovir is principally eliminated by the kidney, in the case of severe renal impairment, including cases of acute renal failure and Fanconi syndrome- dosage adjustment is required in all patients with creatinine clearance <50 ml/min, as detailed in table.

Contraindications

Usually none. However, Tenofovir is contraindicated to the patients who have hypersensitivity to any components of this drug.

Side Effects

The most common side effects are nausea, vomiting, diarrhoea, unusual stomach discomfort, fatigue etc.

Drug Interaction

Co-administration of Tenofovir with antiretroviral, entecavir, lamivudine, methadone, oral contraceptives, ribavirin and tacrolimus did not result in significant drug interactions. However, since Tenofovir is predominantly eliminated by the kidney, co-administration with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either drug.